In this study, we aim to further characterize skin rashes induced by different immunotherapy targets, e.g., anti-PD1 monotherapy (aPD1) or combined anti-PD1/anti-CTLA4 (P+C) therapy. This evidence concerns the gene PDCD1 and Skin rash.